The class of cancer therapies known as antibody drug conjugates showed toxic drug payloads can be delivered to tumors in a targeted way. The first ADCs delivered chemotherapy, but the field is also ...
LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads ...
- Results presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2024 - HOPEWELL, N.J.--(BUSINESS WIRE)--Gennao Bio, a privately held genetic medicines company ...
SAN FRANCISCO and SUZHOU, China, April 29, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
Ottawa, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The global antitumor ADC drugs market size is calculated at USD 8.33 billion in 2026 and is expected to reach around USD 24.75 billion by 2035, growing at a ...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated ...
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces ...
(MENAFN- GlobeNewsWire - Nasdaq) The global antitumor ADC drugs market size is valued at USD 7.38 billion in 2025 and is predicted to hit around USD 24.75 billion by 2035, rising at a 12.86% CAGR, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback